【摘要】 目的:以力百汀(阿莫西林克拉维酸)新剂型为试验药,头孢呋辛、头孢克洛为对照药,力百汀通过/500/125mg两次口服给药,治疗成年人慢性支气管炎急性发作,评价前者的临床安全性和有效性。方法:随机、单盲、平行法对照研究。结果:三组各完成合格病例例,力百汀组、头孢呋辛组及头孢克洛组的临床有效率分别为、及,细1291.7%83.3%91.7%菌清除率分别为、及,不良反应发生率为、和,三组比较,临床有效率及细菌清除率均无显著性差100%90%71.4%8.3%00异。结论:力百汀新剂型两次口服给药,能安全有效地用于治疗成年慢性支气管炎急性发作。500/125mg更多还原

【Abstract】 Objective:The safty and efficacy of Augmentin (amoxicillin/clavulanic acid 500/125mg) was evaluated through clinical study in treating acute exacerbation of chronic bronchitis. Methods: A randomized-controlled clinical trial on Augmentin, cefuroxime and cefaclor against AECB was designed, Thirty-six patients were enrolled, who were divided into three groups, and each group included twelve patients. Augmentin 625mg Bid×××7d; cefuroxime 250mg Bid7d; cefaclor 250mg Tid7d. Results: The clinical effective rates of augmentin was 91.7%, compared with 83.7% of cefuroxime and 91.7% of cefaclor. The bacterial eradication rate was similar among three groups. Incidence of adverse reactions was 8.3% (1/12) in Augmentin group. Conclusion: The efficacy and safty of Augmentin in treating AECB was reliable.更多还原